ACE-031: Myostatin Pathway Research Profile

ACE-031 was supposed to be a breakthrough for boys with Duchenne muscular dystrophy. Early trials showed lean body mass climbing by 3-5% in just weeks, muscle volume expanding without exercise, and the kind of pharmacological effects that had researchers talking about reversing the irreversible. Then, in April 2011, Acceleron Pharma and Shire announced they were halting all clinical trials. The problem wasn't that ACE-031 didn't work—it worked too well, binding to more than just myostatin and triggering vascular side effects that made continuing untenable.

The rise and fall of ACE-031 offers one of the clearest case studies in the challenges of myostatin inhibition. It wasn't a traditional peptide at all, but a fusion protein—a decoy receptor designed to trap myostatin before it could signal muscle cells to stop growing. The science was elegant. The results were measurable. But biology doesn't honor precision when your molecular target shares structural homology with proteins that regulate vascular remodeling.

This article traces what ACE-031 was, how it worked, why it failed, and what its development taught the field about the distance between promising mechanisms and clinically viable therapies.

Quick Facts
What Is ACE-031?
Mechanism of Action: The Myostatin Trap
Clinical Research and Trial Results
Why ACE-031 Was Discontinued
Lessons for Myostatin Inhibition Research
Legal Status and Regulatory Context
Frequently Asked Questions
The Bottom Line

Quick Facts

Property	Details
Full Name	ACE-031 (also known as Ramatercept)
Type	Fusion protein: Activin receptor type IIB extracellular domain fused to human IgG1-Fc
Developer	Acceleron Pharma (in collaboration with Shire)
Primary Target	Myostatin and related TGF-β superfamily ligands
Mechanism	Soluble decoy receptor that binds and neutralizes myostatin, activins, GDF-11, and BMPs
Original Indication	Duchenne muscular dystrophy (DMD)
Clinical Status	Discontinued (2013)
Reason for Termination	Vascular safety concerns—epistaxis, gum bleeding, telangiectasias attributed to BMP9/BMP10 inhibition
FDA Designation	Received FDA Fast Track designation for DMD (2010), subsequently abandoned
Half-Life	10-15 days

What Is ACE-031?

ACE-031 is a soluble form of the activin type IIB receptor (ActRIIB) fused to the Fc region of human immunoglobulin G1 (IgG1). In simpler terms, it's a lab-engineered protein designed to circulate in the bloodstream and intercept signaling molecules that would otherwise tell muscles to stop growing.

The name "ACE-031" is a proprietary identifier from Acceleron Pharma, the Cambridge, Massachusetts-based biotech that developed it. Some sources refer to it as "Ramatercept," particularly in the context of its INN (International Nonproprietary Name).

Unlike traditional peptides like BPC-157 or TB-500, ACE-031 is not a short amino acid chain. It's a fusion protein—a molecule created by linking the extracellular domain of a cell-surface receptor to an antibody fragment. This fusion serves two purposes: the receptor domain binds target ligands, and the Fc domain extends the protein's half-life in circulation, allowing less frequent dosing.

ACE-031 was developed specifically for conditions where muscle wasting is a primary feature, with Duchenne muscular dystrophy as the lead indication. Research published in PubMed described it as a myostatin inhibitor, but this label understates the molecule's promiscuity. ACE-031 binds not only myostatin (GDF-8) but also activins, GDF-11, and certain bone morphogenetic proteins (BMPs), all of which signal through the activin type IIB receptor.

The molecule reached Phase 2 clinical trials in both healthy volunteers and boys with Duchenne muscular dystrophy before being permanently discontinued in 2013 after safety concerns emerged.

Mechanism of Action: The Myostatin Trap

ACE-031 works by mimicking the natural activin type IIB receptor that sits on the surface of muscle cells. Under normal circumstances, myostatin—a TGF-β superfamily member produced by muscle tissue—binds to ActRIIB, activates intracellular signaling through SMAD2/3 transcription factors, and suppresses muscle growth. This is biology's brake pedal on muscle mass.

ACE-031 removes that brake by acting as a decoy. As a soluble receptor, it circulates freely in the bloodstream, intercepting myostatin and related ligands before they can reach their membrane-bound receptors on muscle cells. Once bound to ACE-031, these ligands are neutralized—they can't signal, and muscle growth proceeds unchecked.

Research published in the Journal of Applied Physiology demonstrated that administration of a soluble ActRIIB receptor in mice caused muscle mass increases of up to 60% in just two weeks. The effects were fiber-type independent, meaning both slow-twitch and fast-twitch muscle fibers responded to the treatment. Wet muscle weights of the soleus, plantaris, gastrocnemius, and extensor digitorum longus increased by 33%, 44%, 46%, and 26%, respectively.

The mechanism is broader than myostatin inhibition alone. ACE-031 binds:

Myostatin (GDF-8): The primary negative regulator of muscle mass
GDF-11: Structurally similar to myostatin, also inhibits muscle growth
Activin A: Another TGF-β ligand involved in muscle and metabolic regulation
BMP9 and BMP10: Bone morphogenetic proteins critical for vascular remodeling

This broad binding profile is both ACE-031's strength and its downfall. By targeting multiple ligands, it produced more dramatic increases in muscle mass than myostatin-specific antibodies. But by also binding BMP9 and BMP10, it interfered with endothelial function, leading to the vascular side effects that ended its development.

Studies comparing ActRIIB-Fc to myostatin-specific antibodies found that the broader-spectrum approach resulted in greater muscle hypertrophy, but at the cost of less selectivity. The same mechanism that made ACE-031 effective made it unsafe.

Clinical Research and Trial Results

ACE-031 progressed through early-stage clinical trials with measurable biological effects before being terminated. The data that emerged tells a story of efficacy tempered by unacceptable risk.

Phase 1 Trial in Healthy Volunteers

The first human trial of ACE-031 was a single ascending-dose study published in Muscle & Nerve. Forty-eight healthy, postmenopausal women received a single subcutaneous injection of ACE-031 at doses ranging from 0.02 mg/kg to 3.0 mg/kg, or placebo, in a 3:1 randomized, double-blind design.

Key findings:

Lean body mass increased: In the 3 mg/kg group, total body lean mass rose by 3.3% at day 29 (measured by DXA), with thigh muscle volume increasing by 5.1% (measured by MRI). Both changes were statistically significant (P = 0.03).
Sustained effects: Single doses of 1 mg/kg and 3 mg/kg produced increases in lean body mass as early as day 15 that persisted through day 57. Placebo subjects saw a 0.2% decrease in lean mass, while those receiving 1 mg/kg gained 2.4% and those receiving 3 mg/kg gained 2.6%.
Long half-life: ACE-031's mean terminal half-life was 10-15 days, supporting every-other-week or monthly dosing schedules.
Biomarker changes: Serum markers suggested improvements in bone and fat metabolism, hinting at effects beyond muscle.

The trial was generally well-tolerated, and the results were considered proof-of-concept that ACE-031 could increase muscle mass in humans.

Phase 2 Trial in Duchenne Muscular Dystrophy

The pivotal trial in boys with Duchenne muscular dystrophy (NCT01099761) enrolled ambulatory boys ages 5-11 years with confirmed DMD mutations. This was a randomized, double-blind, placebo-controlled, ascending-dose study. Participants received ACE-031 via subcutaneous injection every two weeks for 12 weeks.

Study design:

Primary objective: Safety evaluation
Secondary endpoints: Lean body mass, fat mass, bone mineral density (BMD), and six-minute walk test (6MWT) distance

Results:

Safety profile: ACE-031 was not associated with serious or severe adverse events during the treatment period.
Pharmacodynamic effects: There were trends toward increased lean mass, decreased fat mass, improvements in BMD, and gains in 6MWT distance—all signals consistent with the drug's mechanism.
Early termination: Despite the absence of severe adverse events in the trial itself, the study was halted after the second dosing cohort due to reports of epistaxis (nosebleeds), gum bleeding, and telangiectasias (dilated blood vessels in the skin) in other concurrent studies.

The DMD trial data suggested biological activity, but the vascular findings in parallel studies triggered a company-wide halt. Clinical Trials Arena reported that Acceleron and Shire suspended all ACE-031 trials in April 2011 to fully understand these events.

A planned open-label extension study (NCT01239758) was also terminated before completion.

Preclinical Studies

Before reaching human trials, ACE-031 demonstrated robust effects in animal models:

Administration in wild-type mice led to 16% increases in body weight and 26-46% increases in individual muscle weights by the end of treatment.
In the mdx mouse (a model of Duchenne muscular dystrophy), ACE-031 improved muscle force generation and reduced muscle damage markers.
A 2025 bioRxiv preprint reported that ACE-031 increased muscle mass and grip strength in the common marmoset, a nonhuman primate model, further supporting its translational potential.

These preclinical results were compelling enough to earn ACE-031 FDA Fast Track designation for DMD in 2010, a regulatory pathway designed to expedite development of drugs for serious conditions with unmet medical need.

Why ACE-031 Was Discontinued

In April 2011, Acceleron Pharma and Shire announced that all ACE-031 clinical trials were being placed on hold. Two years later, in May 2013, the companies formally concluded their collaboration and abandoned the program entirely.

The reason: vascular side effects linked to ACE-031's off-target binding of BMP9 and BMP10.

The Vascular Problem

The adverse events that halted ACE-031 included:

Epistaxis: Nosebleeds
Gum bleeding: Minor but recurrent bleeding from the gums
Telangiectasias: Small dilated blood vessels visible on the skin surface
Erythema: Skin redness

According to research published in PMC, these effects were attributed to cross-inhibition of BMP9 and BMP10, ligands that play critical roles in endothelial cell function and vascular remodeling. BMP9 signals through activin receptor-like kinase 1 (ALK1), a receptor expressed on endothelial cells. Disrupting this pathway can lead to abnormal blood vessel formation and increased vascular fragility.

While the individual events were not life-threatening, they represented a pattern of vascular instability. Regulators and the companies concluded that the risk-benefit profile was unfavorable, particularly for a chronic treatment in a pediatric population.

The irony is that ACE-031's broad ligand-binding profile—its ability to inhibit not just myostatin but also activins and GDF-11—was what made it more effective than myostatin-specific antibodies at increasing muscle mass. But that same lack of specificity made it unsafe.

What Happened to the Patients?

The statement from Acceleron and Shire emphasized that the adverse events were not, in themselves, considered dangerous. The Muscular Dystrophy Association quoted the companies as saying the minor bleeding and dilated blood vessels needed to be "fully understood" before proceeding. No serious injuries were reported in the DMD trial itself.

Still, the decision to halt was swift and final. No restart was ever attempted.

Lessons for Myostatin Inhibition Research

The failure of ACE-031 didn't end myostatin research—it refined it. The molecule's development and discontinuation clarified the challenges inherent in targeting the TGF-β superfamily and shaped the next generation of muscle-growth therapeutics.

Lesson 1: Specificity Matters

ACE-031 bound every ligand that signals through the activin type IIB receptor: myostatin, activin A, GDF-11, BMP9, and BMP10. This made it powerful but indiscriminate. Research reviews in The Journals of Gerontology noted that the lack of specificity in early myostatin inhibitors raised the risk of off-target tissue effects.

Subsequent programs focused on improving selectivity:

ACE-2494: Acceleron's next-generation ActRIIB ligand trap was engineered to avoid BMP9 and BMP10 binding. Studies in Neuromuscular Disorders showed that ACE-2494 increased muscle and bone mass in mice without inhibiting BMP9/BMP10-induced SMAD signaling, suggesting a safer vascular profile.
Myostatin-specific antibodies: Drugs like domagrozumab and landogrozumab were designed to bind only myostatin, not related ligands. While they showed less dramatic muscle gains than ACE-031, they avoided vascular complications.

Lesson 2: Functional Redundancy in Muscle Signaling

Research in PNAS demonstrated that muscle growth is regulated not by myostatin alone but by multiple ligands signaling through both activin type IIA and type IIB receptors. This means that even highly specific myostatin inhibitors may not produce the same magnitude of muscle growth as broader-spectrum approaches.

This creates a dilemma: narrow-spectrum drugs are safer but less effective; broad-spectrum drugs are more effective but riskier. The optimal balance remains an open question.

Lesson 3: Biomarkers Don't Always Predict Clinical Outcomes

ACE-031 hit every surrogate endpoint researchers hoped for: increased lean mass, improved muscle volume, favorable changes in bone and fat biomarkers. Yet it failed because of an effect—vascular disruption—that wasn't anticipated or measured in the initial study design.

A 2021 review in Frontiers in Pharmacology on lessons from discontinued DMD drugs emphasized that early-stage biomarker success doesn't guarantee long-term safety or functional benefit. Phase 2 is where hidden liabilities emerge.

Lesson 4: The Importance of Long-Term Safety Data

ACE-031's DMD trial lasted only 12 weeks. The vascular events that halted the program emerged relatively early, but chronic administration over months or years might have revealed even more significant complications. This underscored the need for extended observation periods, especially in pediatric populations.

What Came After ACE-031?

The field didn't abandon myostatin inhibition; it pivoted. Current approaches include:

Bimagrumab (Novartis): A dual ActRIIA/ActRIIB antibody that blocks multiple ligands but was engineered for better tolerability. Studies in PNAS showed that dual receptor blockade produced maximal skeletal muscle hypertrophy, but development has been slow.
Follistatin: An endogenous myostatin antagonist being explored as a gene therapy vector. Unlike ACE-031, follistatin doesn't directly bind BMP9.
CJC-1295 and other GHRH analogs: Indirect muscle growth strategies that work through growth hormone pathways rather than myostatin inhibition.

ACE-031 remains a cautionary tale: elegant mechanism, measurable effects, and a failure that taught the field as much as success would have.

Legal Status and Regulatory Context

ACE-031 is not approved for any medical use. Development was permanently discontinued in 2013, and the molecule has no regulatory status in the United States, Europe, or any other jurisdiction.

FDA Status

ACE-031 received FDA Fast Track designation for Duchenne muscular dystrophy in 2010, a regulatory mechanism intended to speed the development and review of drugs for serious conditions. That designation became moot when Acceleron and Shire abandoned the program.

The FDA did not issue a formal safety warning or regulatory action against ACE-031 because the companies voluntarily halted trials before any regulatory intervention became necessary.

WADA and Sports

ACE-031 appears on the World Anti-Doping Agency (WADA) Prohibited List under the category of "Other Growth Factors and Growth Factor Modulators." Its ability to increase muscle mass made it a concern for athletic doping, even though it never became commercially available.

WADA's classification reflects the theoretical risk that research-grade or compounded versions could be diverted for performance enhancement.

Current Availability

ACE-031 is not manufactured or distributed by any pharmaceutical company. Some research chemical suppliers claim to sell ACE-031 for "research purposes only," but these products are unregulated, untested, and of unknown provenance. There is no legitimate clinical or personal use for ACE-031 outside of archived research settings.

The molecule exists in the literature and in the memories of those who worked on it, but not in clinics or pharmacies.

Frequently Asked Questions

What is ACE-031?

ACE-031 is a fusion protein consisting of the extracellular domain of the activin type IIB receptor (ActRIIB) fused to the Fc region of human IgG1. It was developed by Acceleron Pharma as a myostatin inhibitor for the treatment of Duchenne muscular dystrophy. It works by binding to myostatin and related TGF-β ligands, preventing them from signaling muscle cells to stop growing. The program was discontinued in 2013 due to vascular safety concerns.

Is ACE-031 the same as myostatin?

No. Myostatin (GDF-8) is a naturally occurring protein that inhibits muscle growth. ACE-031 is a synthetic fusion protein designed to neutralize myostatin by binding to it before it can reach its receptor on muscle cells. ACE-031 is a therapeutic agent that blocks myostatin's effects; it is not myostatin itself.

Why was ACE-031 discontinued?

ACE-031 was discontinued due to vascular side effects observed during clinical trials, including nosebleeds, gum bleeding, and dilated blood vessels (telangiectasias). These effects were linked to ACE-031's off-target inhibition of BMP9 and BMP10, proteins that regulate endothelial cell function and blood vessel remodeling. Although the individual events were not severe, the pattern raised concerns about long-term vascular safety, particularly in a pediatric population requiring chronic treatment.

Did ACE-031 increase muscle mass in humans?

Yes. In a Phase 1 trial in healthy postmenopausal women, a single 3 mg/kg dose of ACE-031 increased lean body mass by 3.3% and thigh muscle volume by 5.1% at day 29. A Phase 2 trial in boys with Duchenne muscular dystrophy showed trends toward increased lean mass, but was terminated before final results could be analyzed due to safety concerns.

How does ACE-031 compare to follistatin?

Both ACE-031 and follistatin inhibit myostatin, but through different mechanisms. ACE-031 is a soluble decoy receptor that binds myostatin and related ligands in the bloodstream. Follistatin is a naturally occurring binding protein that also neutralizes myostatin and activins, but it binds a somewhat different set of ligands and doesn't target BMP9/BMP10. Follistatin has not been associated with the vascular side effects that ended ACE-031's development, but it has also not advanced as far in clinical trials for muscle-wasting conditions.

Is ACE-031 legal to use?

ACE-031 is not approved by the FDA or any other regulatory agency for medical use. It is not available through legitimate pharmaceutical channels. Some research chemical suppliers claim to sell ACE-031, but these products are unregulated and of unknown quality. ACE-031 is also on the WADA Prohibited List, making it illegal for use in competitive sports. There is no legal, safe, or medically supervised context for ACE-031 use.

Can ACE-031 be used for bodybuilding or performance enhancement?

No. ACE-031 is not approved for any use, including bodybuilding or athletic performance. Its vascular side effects—nosebleeds, bleeding, and abnormal blood vessel formation—make it dangerous, particularly with repeated dosing. The molecule was abandoned specifically because these risks outweighed its muscle-building benefits. Using research chemicals or unapproved compounds for performance enhancement carries significant health and legal risks.

What happened to the boys in the Duchenne muscular dystrophy trial?

The boys enrolled in the ACE-031 DMD trial did not experience serious or severe adverse events during the 12-week treatment period. The trial was halted proactively based on vascular events observed in concurrent studies, not because of harm to the DMD participants themselves. The safety concerns were considered a precautionary measure to prevent potential long-term complications.

The Bottom Line

ACE-031 represents both the promise and the peril of myostatin inhibition. It worked—lean body mass increased, muscle volume expanded, and biomarkers moved in favorable directions. The science was sound. The results were real. But biology doesn't respect precision when your drug binds to proteins that regulate blood vessel integrity.

The molecule's failure was not a failure of the myostatin hypothesis. Myostatin is still a validated target for muscle wasting, and related growth factors like IGF-1 LR3 and MGF continue to be studied for their anabolic effects. ACE-031's discontinuation was a failure of selectivity—a cautionary tale about the risks of broad-spectrum inhibition in a family of signaling molecules as tightly interconnected as the TGF-β superfamily.

For researchers, ACE-031 clarified what needs to be solved: how to block myostatin's muscle-suppressing effects without disrupting vascular remodeling, bone signaling, or metabolic regulation. The next generation of ActRIIB-based therapies—like ACE-2494 and bimagrumab—incorporated lessons from ACE-031's development, engineering in more selectivity and better safety profiles.

For patients with Duchenne muscular dystrophy, ACE-031's discontinuation was another setback in a long series of near-misses. The disease remains without a cure, and the search for effective muscle-preserving therapies continues.

And for anyone encountering ACE-031 in the research chemical market or on athletic forums: the molecule failed clinical development for a reason. No amount of muscle growth justifies vascular instability, and no legitimate medical context exists for its use.

ACE-031 is archived science now—important, instructive, and firmly in the past.

Medical Disclaimer

This article is for educational purposes only and does not constitute medical advice. ACE-031 is not approved by the FDA or any regulatory agency for human use. It is not available through legitimate pharmaceutical channels and should not be used outside of supervised clinical research. The information presented here is based on published scientific literature and is intended to inform, not to recommend or endorse any specific treatment or compound. If you have a medical condition or are considering any therapeutic intervention, consult a qualified healthcare provider.

References

Campbell, C., et al. (2017). Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle & Nerve, 55(4), 458-464. https://pubmed.ncbi.nlm.nih.gov/27462804/
Glasser, C. E., et al. (2013). A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle & Nerve, 47(3), 416-423. https://pubmed.ncbi.nlm.nih.gov/23169607/
Cadena, S. M., et al. (2010). Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. Journal of Applied Physiology, 109(3), 635-642. https://pubmed.ncbi.nlm.nih.gov/20466801/
Muscular Dystrophy Association. (2011). UPDATE: ACE-031 Clinical Trials in Duchenne MD. Quest Magazine. https://www.mda.org/quest/article/update-ace-031-clinical-trials-duchenne-md
Singh, P., et al. (2020). Myostatin Inhibitors: Panacea or Predicament for Musculoskeletal Disorders? Frontiers in Physiology, 11, 531. https://pmc.ncbi.nlm.nih.gov/articles/PMC7571243/
Lee, S. J., et al. (2005). Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proceedings of the National Academy of Sciences, 102(50), 18117-18122. https://www.pnas.org/doi/10.1073/pnas.0505996102
Townley, R., et al. (2015). ACE-2494, a novel GDF ligand trap, increases muscle and bone mass upon systemic administration in mice. Neuromuscular Disorders, 25(Suppl 2), S211-S212. https://www.nmd-journal.com/article/S0960-8966(15)00303-X/abstract
Acceleron Pharma. (2010). Acceleron Pharma Receives FDA Fast Track Designation for ACE-031 for the Treatment of Duchenne Muscular Dystrophy. [Press release]. https://investor.acceleronpharma.com/news/news-details/2010/Acceleron-Pharma-Receives-FDA-Fast-Track-Designation-for-ACE-031-for-the-Treatment-of-Duchenne-Muscular-Dystrophy/default.aspx
Garito, T., et al. (2021). Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy. Frontiers in Pharmacology, 12, 735912. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.735912/full
Rooks, D., et al. (2020). Challenges and Future Prospects of Targeting Myostatin/Activin A Signaling to Treat Diseases of Muscle Loss and Metabolic Dysfunction. The Journals of Gerontology: Series A, 78(Supplement_1), 32-42. https://academic.oup.com/biomedgerontology/article/78/Supplement_1/32/7026116
Woodhouse, L., et al. (2014). Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy. Proceedings of the National Academy of Sciences, 114(47), 12448-12453. https://www.pnas.org/doi/10.1073/pnas.1707925114
ClinicalTrials.gov. Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy. NCT01099761. https://clinicaltrials.gov/study/NCT01099761
Acceleron Pharma. (2009). Acceleron Pharma's ACE-031 Increases Lean Body Mass in Phase 1 Single Dose Clinical Trial. [Press release]. https://www.flagshippioneering.com/news/press-release/acceleron-pharmas-ace-031-increases-lean-body-mass-phase-1-single-dose-clinical-trial
Lach-Trifilieff, E., et al. (2015). Administration of soluble activin receptor 2B increases bone and muscle mass in a mouse model of osteogenesis imperfecta. Bone Research, 3, 15042. https://www.nature.com/articles/boneres201442
Saitoh, M., et al. (2017). Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy. JCSM Clinical Reports, 2(1), e00037. https://onlinelibrary.wiley.com/doi/full/10.17987/jcsm-cr.v2i1.37

Table of Contents